Abbott Laboratories (ABT)
|Net Income (ttm)||7.89B|
|Ex-Dividend Date||Jan 12, 2023|
|Day's Range||110.66 - 112.33|
|52-Week Range||93.25 - 130.79|
|Price Target||122.18 (+9.29%)|
|Earnings Date||Jan 25, 2023|
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipi... [Read more]
In 2021, ABT's revenue was $43.08 billion, an increase of 24.47% compared to the previous year's $34.61 billion. Earnings were $7.07 billion, an increase of 57.31%.Financial Statements
According to 29 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $122.18, which is an increase of 9.29% from the latest price.
ZBH vs. ABT: Which Stock Is the Better Value Option?
Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today's market. They offer relatively high yields and at least some value while projec...
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare ...
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective t...
The downside can be attributed to a manufacturing disruption during 2022 of certain infant formula products at Abbott's (ABT) Sturgis, MI facility.
Abbott Laboratories tops Q4 earnings
Yahoo Finance's Anjalee Khemlani joins the Live show to break down fourth-quarter earnings for Abbott Laboratories.
Abbott (ABT) delivered earnings and revenue surprises of 14.44% and 6.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Abbott reports fourth-quarter adjusted earnings that beat Wall Street estimates but sales fall 12% from a year earlier.
Abbott Laboratories ABT had better-than-expected earnings and revenue in the fourth quarter of 2022, though headwinds from its baby formula business and declining COVID-19 test sales are still weighin...
Abbott Laboratories on Wednesday reported lower-than-expected medical device sales in the fourth quarter as COVID-19 curbs in China and supply-chain issues hit its international operations, dragging s...
Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent Full-year 2022 GAAP diluted EPS of $3.91; a...
Earnings Exchange: KMB, ABT & MSFT
David Katz, Matrix Asset Advisors CIO, joins ‘The Exchange' to discuss a few stocks ahead of earnings, including Kimberly-Clark, Abbott and Microsoft.
For perspective, Abbott expects total Covid-19 related sales of $500 million in Q4, compared to $2.3 billion in the prior-year quarter.
Final Trades: Abbott Labs, GE Healthcare, Viper Energy and more
The "Halftime Report" traders give their top picks to watch for the second half.
Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.
The FDA found multiple unsanitary conditions at Abbott's plant in Michigan last year, following its recall of its baby formula, prompting a nationwide shortage.
Abbott Laboratories' Michigan plant, which was at the center of the U.S. baby formula shortage last year, is being investigated by the Justice Department, the Wall Street Journal reported on Friday.
The Justice Department is investigating conduct at the Abbott Laboratories infant-formula plant in Sturgis, Mich., that led to its shutdown last year and worsened a nationwide formula shortage, people...
Federal prosecutors are probing conduct at Abbott's baby-formula plant in Michigan, which the company temporarily shutdown last year after a potentially deadly bacteria was found
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ABBOTT ALERT: Bragar Eagel & Squire, P.C. is Investigating Abbott Laboratories on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Abbott Laboratories (NYSE: ABT) on behalf of lo...
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Within Abbott's (ABT) Established Pharmaceuticals Division (EPD), new product launches across key markets have been majorly boosting business in recent months.
Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis
Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant Transcatheter aortic valve implantation (TAVI) ...